Age at natural menopause genetic risk score in relation to age at natural menopause and primary open-angle glaucoma in a US-based sample.

OBJECTIVE: Several attributes of female reproductive history, including age at natural menopause (ANM), have been related to primary open-angle glaucoma (POAG). We assembled 18 previously reported common genetic variants that predict ANM to determine their association with ANM or POAG.
METHODS: Using data from the Nurses' Health Study (7,143 women), we validated the ANM weighted genetic risk score in relation to self-reported ANM. Subsequently, to assess the relation with POAG, we used data from 2,160 female POAG cases and 29,110 controls in the National Eye Institute Glaucoma Human Genetics Collaboration Heritable Overall Operational Database (NEIGHBORHOOD), which consists of 8 datasets with imputed genotypes to 5.6+ million markers. Associations with POAG were assessed in each dataset, and site-specific results were meta-analyzed using the inverse weighted variance method.
RESULTS: The genetic risk score was associated with self-reported ANM (P = 2.2 × 10) and predicted 4.8% of the variance in ANM. The ANM genetic risk score was not associated with POAG (Odds Ratio (OR) = 1.002; 95% Confidence Interval (CI): 0.998, 1.007; P = 0.28). No single genetic variant in the panel achieved nominal association with POAG (P ≥0.20). Compared to the middle 80 percent, there was also no association with the lowest 10 percentile or highest 90 percentile of genetic risk score with POAG (OR = 0.75; 95% CI: 0.47, 1.21; P = 0.23 and OR = 1.10; 95% CI: 0.72, 1.69; P = 0.65, respectively).
CONCLUSIONS: A genetic risk score predicting 4.8% of ANM variation was not related to POAG; thus, genetic determinants of ANM are unlikely to explain the previously reported association between the two phenotypes.

Primary open-angle glaucoma (POAG) is an optic neuropathy strongly influenced by age and intraocular pressure that is a leading cause of irreversible blindness worldwide.[1] Women carry a higher burden of visual disability related to POAG, presumably because they live longer than men.[2] Although women are not necessarily more predisposed to POAG than men, attributes of female reproductive history linked to circulating estrogen levels are related to this disease. Later age at menarche,[3,4] oral contraceptive use,[4,5] early oophorectomy,[6] and earlier age at menopause[7,8] are associated with an increased risk of POAG. In contrast, later age at menopause[9] and postmenopausal hormone use[10,11] were associated with reduced risk of POAG. Interestingly, post hoc analysis of a randomized clinical trial in the Women's Health Initiative revealed that postmenopausal estrogen use was associated with a modest 0.5 mm Hg reduction in intraocular pressure,[12] the only known modifiable risk factor for POAG.

Early menopause is associated with several nonocular diseases.[13,14] With respect to glaucoma, in the Rotterdam Study, entering menopause before age 45 was associated with a 2.6-fold increased risk of open-angle glaucoma compared to entering menopause after age 50.[7] Among participants 65 years or older in the Nurses’ Health Study, entering menopause at age 54 years or older was associated with a 47% reduced risk of high-tension POAG compared to entering menopause between the ages of 50 to 54.[9] To better understand these results, we evaluated whether this relationship with POAG may be mediated by age at natural menopause (ANM) genetic biomarkers, because ANM is a highly heritable trait.[15-18] Recently, several common genetic variants that predict menopause, a critical step in ovarian aging, have been identified.[19] These variants do not overlap with the variants responsible for estrogen metabolism that we previously reported to be associated with POAG among women[20]; nor do they overlap with known common gene variants for POAG.[21] The nonoverlap between gene variants related to ANM and POAG could reflect the fact that genome-wide significant loci for these traits represent variants with the most stringent P values to reduce false discovery from multiple comparisons. ANM gene variants could represent novel biologically relevant POAG loci with associations that may have been obscured by the use of stringent P values. Assembling ANM gene variants in a panel enhances the power to detect an overall association between ANM genetic variants and POAG while averting the multiple comparisons problem.

We validated the predictive ability of a previously published ANM genetic panel[19] in relation to self-reported ANM in the Nurses Health Study and then determined the association with POAG in a large United States case-control dataset, composed of European-Americans referred to as the National Eye Institute Glaucoma Human Genetics Collaboration Heritable Overall Operational Database (NEIGHBORHOOD).

METHODS

The nurses health study and the national eye institute glaucoma human collaboration heritable overall operational database

The nurses health study (NHS) includes more than 121,000 female nurse participants who answered biennial questionnaires since cohort inception in 1976, including questions on reproductive status and various diseases such as glaucoma.[22] Out of a subset of 11,522 women genotyped on three different high throughput platforms (various generation Illumina arrays specified below, the Illumina OmniExpress and the Affymetrix 6.0 arrays) for 11 disease endpoints, 7,143 had data on ANM and were included in the assessment of the relation between self-reported ANM and genetic risk score for ANM (discussed below). Women with no data on age at menopause or those with surgical menopause, history of pelvic radiation or menopause of unknown type were excluded. Data on menopause status in Nurses’ Health Study has been previously validated.[23]

The national eye institute glaucoma human collaboration heritable overall operational database (NEIGHBORHOOD) dataset represents a genome-wide meta-analysis summary dataset from eight independent studies, including the Nurses’ Health Study, with a total of 3,853 POAG cases and 33,480 controls of European ancestry from the United States. Details regarding the composition of the dataset used can be found in the study by Cooke Bailey et al[24] and in Supplemental Table 1, Supplemental Digital Content 1, http://links.lww.com/MENO/A180. A harmonized definition of POAG across these datasets consisted of the following features: open ocular anterior segment angles, pathologic cupping (cup-disc ratio ≥0.7 in both eyes or inter-eye cup-disc ratio difference ≥ 0.2), or at least one reliable visual field with deficits localizing to the optic nerve without secondary cause; although elevated intraocular pressure was not a criterion for POAG definition, if present, there had to be no secondary causes on anterior segment examination. We used the female-only meta-analyzed data in the NEIGHBORHOOD dataset from 2,160 POAG cases and 29,110 controls. This dataset partially overlapped with the NHS dataset used to assess the relation between ANM genetic risk score and self-reported ANM. From the Nurses’ Health Study, we included 76 POAG cases and 2,488 controls who were genotyped on the Affymetrix 6.0 platform and 259 POAG cases and 1,367 controls who were genotyped on various generation Illumina platforms (317K, 550K, 610K, and the 660W arrays); controls who did not report an eye exam were not included in the POAG analyses.

Formation of the age at natural menopause weighted genetic risk score

The largest genome-wide meta-analysis of ANM included 53,403 women of European descent[19] and identified 19 gene variants that were associated with ANM at the genome-wide significance level. Among the 19 gene variants associated with ANM reported by Stolk et al,[19] 18 were available in the Nurses Health Study and served as the basis for the ANM genetic risk score in our primary analysis. We also formed a larger genetic panel containing 44 common gene variants derived from a genome-wide scan of 69,360 women of European ancestry[25] and present data related to this panel in Supplemental Table 2, Supplemental Digital Content 2, http://links.lww.com/MENO/A181, as these results did not differ from our primary analysis. To evaluate the relationship between ANM genetic risk score and self-reported ANM, genotypes were derived from the merged datasets in Nurses’ Health Study described above. Details regarding how these datasets were merged are available in the supplemental material of the study by Cooke Bailey et al.[24] Briefly, we created three platform-specific datasets (one each for earlier generation Illumina arrays, the Illumina OmniExpress array and the Affymetrix 6.0 array) and imputed the datasets using the 1,000 genomes phase I release. Each dataset underwent extensive quality control measures including analyses within and across the platforms to exclude duplicate samples and related individuals. To decrease false positives in imputation, we used only gene variants that overlap when combining all the datasets. The details of the quality control process used in imputing across platforms have been previously published.[26] Gene variants that would create spurious associations and gene variants with poor imputation quality score at most 0.3 as determined by the MaCH software package designed to infer genotypes at un-typed loci were excluded.

For the NEIGHBORHOOD dataset, we used the meta-analysis results of POAG in women only. Details regarding the composition of the eight NEIGHBORHOOD datasets, genotyping, quality control measures, imputation and meta-analysis can be found in Cooke Bailey et al.[24]

Statistical analyses

To model ANM and POAG, we used multivariable linear regression and logistic regression, respectively. Individual gene variants were coded for the minor allele dosage associated with later-onset of ANM based on their imputation score with values ranging from zero for no alleles up to two, signifying two alleles. The ANM genetic risk score was defined as weighted based on the effect estimate of each gene variant or unweighted, where each gene variant carried equal weight.

In analyses for ANM, we used platform-specific results from the Nurses Health Study and meta-analyzed them with a computational tool called METAL,[27] after ruling out heterogeneity with the Cochran Q-statistic. We adjusted for age in the year 1986, eigenvectors, and 11 disease endpoints including POAG (as genome-wide data in Nurses’ Health Study was intended to assess other outcomes including coronary heart disease, type 2 diabetes, pancreatic cancer, kidney stones, glioma, colon cancer, gout, endometrial cancer, mammographic density, and ovarian cancer) in multivariate analyses.

In analyses for POAG, we used an inverse-variance weighted sum meta-analysis of individual SNP effect estimates from the female-only analysis, as proposed by Aschard.[28] Let β = (βG1, βG2, … βGm), a vector of elements of βGm, which represents the reported effect of the mth selected gene variant on POAG in the meta-analysis summary statistics and   represent the variance of each estimate. Under the assumption of independence between the gene variants (ie, assuming the gene variants’ inter-correlations are negligible),  GRS, the chi-squared for the GRS effect on POAG, can be derived as:

We adjusted for age in years as a linear variable at DNA collection for POAG cases and controls as well as site-specific eigenvectors. To allow for differences in effect among the individuals with extreme values for the genetic risk score, we also considered a model to assess the relation between scores in the less than 10th percentile and more than 90th percentile relative to the middle 80% of genetic risk scores.

RESULTS

Mean ANM in the Nurses’ Health Study sample was 50.6 years (standard deviation = 3.6 y). Age differences between cases and controls were adjusted for in genetic associations with POAG.

Age at natural menopause genetic variants in relation to self-reported ANM in the nurses’ health study

Various studies have reported that between 2.5% to 4.1% of the reported total variance of ANM was explained by genes listed in Table 1.[19] We first tested each variant for association with self-reported ANM in the Nurses’ Health Study using standard univariate linear regression. Almost all were nominally significant (16 of 18) and all showed positive correlation with reported ANM, in agreement with their previously reported effects (Table 1).[19] The weighted gene risk score was 1.19 (Table 1) and the most significant gene locus was rs11668344 (TMEM150B; P = 3.9 × 10−20). When all were simultaneously included in a multivariate model, these 18 gene loci jointly explained 4.8% of the variance of ANM in Nurses’ Health Study, a slightly larger amount than reported in Stolk et al.[19] The association between either the unweighted or weighted genetic risk scores and self-reported ANM was highly significant with P values of 1.2 × 10–61 and 2.2 × 10–77, respectively. A 1.5-year difference in ANM between women at the 5th percentile (ANM = 49.0 y) and the 95th percentile (ANM = 50.5 y) of the genetic risk score was observed.

TABLE 1

ANM single nucleotide polymorphisms in relation to self-reported ANM in the Nurses’ Health Study (n = 7,143)

SNP	chr	Gene	A0/A1	Reported effect	Beta	P
SNP analysis
rs4246511	1	RHBDL2	T/C	0.24	0.315	6.5 × 10−6
rs1635501	1	EXO1	T/C	0.16	0.261	3.3 × 10−5
rs2303369	2	FNDC4	C/T	0.18	0.259	4.5 × 10−5
rs10183486	2	TLK1	C/T	0.20	0.161	0.012
rs4693089	4	HELQ	G/A	0.23	0.296	1.7 × 10−6
rs890835	5	RNF44	A/C	0.18	0.159	0.10
rs365132	5	UIMC1	T/G	0.29	0.274	5.2 × 10−6
rs2153157	6	SYCP2L	A/G	0.17	0.228	2.0 × 10−4
rs2517388	8	ASH2L	G/T	0.26	0.254	2.5 × 10−3
rs12294104	11	near MPPED2 C11orf46	T/C	0.23	0.159	0.054
rs2277339	12	PRIM1	T/G	0.38	0.481	6.9 × 10−6
rs3736830	13	KPNA3	C/G	0.18	0.207	0.013
rs4886238	13	TDRD3	A/G	0.17	0.157	0.017
rs2307449	15	POLG	T/G	0.18	0.187	0.0030
rs10852344	16	near TNFRSF17 RUNDC2A, GSPT1	C/T	0.17	0.113	0.076
rs11668344	19	TMEM150B	A/G	0.42	0.588	3.9 × 10−20
rs12461110	19	NLRP11	G/A	0.16	0.330	32.4 × 10−7
rs16991615	20	MCM8	A/G	0.95	1.170	2.7 × 10−17
GRS-based analysisa
GRS					0.27	1.2 × 10−61
wGRS					1.19	2.2 × 10−77

ANM, age at natural menopause; GRS, Genetic Risk Score; SNP, single nucleotide polymorphism.

GRS corresponds to the sum of all risk alleles; wGRS corresponds to the weighted sum of all risk alleles, where weights were defined as the beta coefficient of each SNP from Stolk et al.[19] A0/A1 corresponds to the reference and coded allele, where the coded allele is associated later ANM.

Age at menopause gene variants in relation to primary open-angle glaucoma in the NEIGHBORHOOD dataset

We tested the association between the 18 ANM gene variants and POAG in the NEIGHBORHOOD dataset using the summary statistics from the female-specific portion genome wide scan but no single locus showed even nominal associations with POAG (P ≥ 0.20; Table 2). We then tested the effect of either the unweighted or the weighted genetic risk score on POAG, first treating these scores as continuous variables, and subsequently, allowing for differences in effect among the individuals with extreme values. Neither the un-weighted genetic risk score (odds ratio (OR) = 1.013; 95% confidence interval (CI): 0.990, 1.036), nor the weighted score (OR = 1.002; 95% CI: 0.998, 1.007) was associated with POAG. The lowest 10th and highest 90th percentiles of the weighted genetic risk scores were also not associated with POAG (OR = 0.75; 95% CI: 0.47, 1.21; P = 0.23 and OR = 1.10; 95% CI: 0.72, 1.69; P = 0.65, respectively). For the larger 44-member weighted and unweighted ANM genetic risk scores, we found identical null associations with POAG; the P values were 0.42 and 0.87, respectively (Supplemental Table 2, Supplemental Digital Content 2, http://links.lww.com/MENO/A181). Only a PIWIL1 locus (rs12824058) showed nominal association with POAG (P = 0.014) but the OR was in the opposite direction than expected (1.12) given the variant allele was associated with later ANM.

TABLE 2

Age at natural menopause single nucleotide polymorphisms in relation to primary open-angle glaucoma in the National Eye Institute Glaucoma Human Genetics Collaboration Heritable Overall Operational Database (2,160 cases and 29,111 controls)

SNP	chr	Gene	A0/A1	OR	95% CI	P
SNP analysis
rs4246511	1	RHBDL2	T/C	1.04	(0.92,1.12)	0.42
rs1635501	1	EXO1	T/C	1.02	(0.92,1.10)	0.65
rs2303369	2	FNDC4	C/T	1.03	(0.93,1.11)	0.49
rs10183486	2	TLK1	C/T	0.95	(0.89,1.07)	0.24
rs4693089	4	HELQ	G/A	1.01	(0.92,1.10)	0.77
rs890835	5	RNF44	A/C	1.06	(0.89,1.17)	0.40
rs365132	5	UIMC1	T/G	1.01	(0.92,1.10)	0.81
rs2153157	6	SYCP2L	A/G	1.02	(0.93,1.10)	0.61
rs2517388	8	ASH2L	G/T	1.03	(0.90,1.14)	0.66
rs12294104	11	near MPPED2 C11orf46	T/C	0.96	(0.87,1.11)	0.50
rs2277339	12	PRIM1	T/G	1.02	(0.86,1.18)	0.80
rs3736830	13	KPNA3	C/G	0.99	(0.88,1.12)	0.91
rs4886238	13	TDRD3	A/G	1.06	(0.93,1.13)	0.20
rs2307449	15	POLG	T/G	0.98	(0.91,1.09)	0.65
rs10852344	16	near TNFRSF17 RUNDC2A, GSPT1	C/T	1.01	(0.92,1.10)	0.80
rs11668344	19	TMEM150B	A/G	1.00	(0.91,1.10)	0.99
rs12461110	19	NLRP11	G/A	0.98	(0.90,1.09)	0.64
rs16991615	20	MCM8	A/G	1.11	(0.87,1.25)	0.27
GRS-based analysisa
GRS				1.013	(0.990, 1.036)	0.28
wGRS				1.002	(0.998, 1.007)	0.28

ANM, Age at natural menopause; CI, confidence interval; GRS, Genetic Risk Score; OR, odds ratio; SNP, single nucleotide polymorphism.

GRS corresponds to the sum of all risk alleles. wGRS corresponds to the weighted sum of all risk alleles, where weights were defined as the beta coefficient of each SNP from Stolk et al.[19] A0/A1 corresponds to the reference and coded allele, where the coded allele is associated later ANM.

DISCUSSION

The ANM GRS panel was significantly predictive of self-reported ANM in the NHS, although it only explained 4.8% of the variance of ANM. This finding is consistent with previous reports in populations of varying ethnicities.[29,30] Interestingly, although a few ANM genes are directly implicated in ovarian function,[31,32] many are implicated in DNA repair mechanisms.[25] Although our reported relation between ANM gene variants and self-reported ANM may be somewhat inflated due to the 8% overlap between Nurses’ Health Study and Stolk et al[19] they do serve to validate the biomarker panel as reflective of ANM.

We did not observe associations between the ANM genetic risk score and POAG, even when we considered the extremes of the score. Furthermore, none of the gene variants in the ANM panel were even marginally associated with POAG. It is unlikely that the sample was underpowered to find an association. With the large sample size of 2,160 cases and 29,110 controls in NEIGHBORHOOD, we had 80% power to detect an OR of 0.94 or lower for association between the ANM gene panel with POAG. Power dropped to 50% for an OR of 0.96.

We leveraged high throughput genetic data in the largest POAG case-control set currently available in the form of a Mendelian randomization experiment. We used panels of genetic markers that predict ANM in relation to POAG. Agnostic search mechanisms reveal that many of these genes work through DNA repair mechanisms, involving enzymes such as HELQ and POLG, a DNA helicase and DNA polymerase respectively, both of which are strongly associated with ANM (Table 1) but not associated with POAG (Table 2). Epidemiologic research supports the notion that declining estrogen levels are important in POAG pathogenesis.[2-12] Our work suggests that for POAG, genetic[20] and nongenetic exposures influencing estrogen levels[5,9] may be more important than gene-based DNA repair mechanisms that may be more critical for other traits related to ANM such as breast cancer,[25] where positive regulation of cell growth is observed.

17-β estradiol is present in human trabecular meshwork cells[33] that contribute to intraocular pressure generation and estrogen receptors are present on retinal ganglion cells[34] that are selectively targeted for degeneration in POAG. Thus estrogenic input could be responsible for the lower IOP seen after estrogen replacement in postmenopausal women[12] and the neuroprotective effects of estrogen observed in animal models of glaucoma.[35,36] The definitive null association between ANM gene variants and POAG is critically important because it suggests these biomarkers, although related to ANM, are not viable targets to reduce the burden of POAG.

Although assembling genes into a panel serves to distinguish between true and false positive associations, in our instance no single gene in the panel achieved even nominal significance for association with POAG (Table 2). Even when we considered a larger 44-member ANM genetic panel in relation to POAG, our results were unequivocally null (Supplemental Table 2, Supplemental Digital Content 2, http://links.lww.com/MENO/A181), perhaps because the larger panel did not materially expand the biological pathway governing ANM much beyond DNA processing.[25] Furthermore, the expanded panel only increased the variance in reported ANM explained by common gene variants from 4.8% to 6%.[25] Finally, considering POAG participants with either low or extremely high ANM genetic risk scores did not yield significant results. The difference in actual ANM was, however, relatively small for those at the extremes of the genetic risk score—women in the 5th percentile of the GRS had a mean ANM of 49 years, whereas those in the 95th percentile had a mean ANM of 50.5 years. Thus, although the genetic risk score is significantly predictive of ANM, even the extremes of this score may not be able to capture those with extreme actual ANM where associations with POAG have been observed. In the Rotterdam study, for example,[7] the significant association with greater POAG risk was with early menopause (age <45 y) versus after age 50 years, which represented a difference of approximately 5 years in ANM. Although the discovery set for ANM genetic biomarkers was large (n = 38,968),[19] even larger samples may be needed to discover missing heritability for ANM. There are likely hundreds of common genetic biomarkers that contribute to ANM and it may be worth re-examining the relation between genetic markers for ANM and POAG at a later date when more of these markers are known.

This study has some limitations. The findings are restricted to Caucasians and may not be applicable to other ethnic groups, as ANM does vary by ethnicity.[37] Although the genetic panel for ANM explains only a small percentage of the variance in this trait, a larger panel explaining a greater percent of the variance was also not associated with POAG (Supplemental Table 2, Supplemental Digital Content 2, http://links.lww.com/MENO/A181). Furthermore, we previously showed that a genetic panel directly related to estrogen metabolism was associated with POAG in women but not in men.[20] Finally, we did not account for other factors that might influence ANM such as smoking, body mass index, age at menarche, parity, and oral contraceptive use.[37,38]

CONCLUSIONS

Overall, although several attributes of female reproductive health are related to POAG, existing ANM gene variants, either individually or collectively are not related to glaucoma risk, indicating that genetic determinants of ANM are unlikely to explain the previously reported association between the two phenotypes.

Funding/support: The NIH/NEI R01EY022305 (J.L.W.) supports data collection and analysis for the National Eye Institute Glaucoma Human Genetics Collaboration Heritable Overall Operational Database (NEIGHBORHOOD) consortium. Support for collection of cases, controls, and analysis for individual datasets is as follows. Genotyping services for the predecessor National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) study were provided by the Center for Inherited Disease Research (CIDR) and were supported by the National Eye Institute (NEI) through grant HG005259-01 (J.L.W.). In addition, CIDR is funded through a federal contract from the National Institutes of Health to The Johns Hopkins University—contract number HHSN268200782096C. Genotyping for the Mass Eye and Ear dataset and some Nurses Health Study (NHS) and Health Professionals Follow-up Study (HPFS) participants that formed the Glaucoma Genes and Environment (GLAUGEN) study was completed at the Broad Institute and supported by GENEVA project grant HG004728 (L.R.P.) and U01-HG004424 (Broad Institute). NIH/NHGRI U01 HG004446 (C Laurie) supported genotype data cleaning and analysis for the GLAUGEN study. The NEI through ARRA grants 3R01EY015872-05S1 (J.L.W.) and 3R01EY019126-02S1 (M.A.H.) supported the collection and processing samples for the NEIGHBOR dataset. The funding for the collection of NEIGHBOR cases and controls was provided by NIH grants: EY015543 (R.R.A.), U02HG004608 (M.H.B.), HG006389 (M.H.B.), UL1TR000427 (M.H.B.), EY006827 (D.G.), HL73042, HL073389, EY13315 (M.A.H.); CA87969, CA49449, CA55075, EY009149 (PR Lichter), HG004608 (C McCarty), EY008208 (F.M.), EY015473 (L.R.P.), EY012118 (M.A.P.-V.), EY015682 (T.R.), EY011671 (J.E.R.), EY09580 (J.E.R.), EY013178 (J.S.S.), EY010886 (J.L.W.), EY009847 (J.L.W.), EY011008, EY144428 (K Zhang), EY144448 (K Zhang), EY18660 (K Zhang), and Research to Prevent Blindness (multiple institutions). The collection of Marshfield clinic cases and controls was supported by 1U02HG004608-01, 5U01HG006389-02, and NCATS/NIH grant UL1TR000427. In addition, some NHS/HPFS cases and controls and analysis of genome-wide data were supported by R01 CA131332 (RM Tamimi, I De Vivo), UM1 CA186107, UM1 CA167552, R01 CA49449, P01 CA87969. The Women's Genome Health Study (WGHS) is supported by HL043851 and HL080467 from the National Heart, Lung, and Blood Institute and CA047988 from the National Cancer Institute, the Donald W. Reynolds Foundation and the Foundation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen. POAG case identification in Women's Genome Health Study was supported by 3RO1 EY015473-05S1 (LR Pasquale). Blood collection at New York Eye & Ear Infirmary was supported by the New York Glaucoma Research Institute.

Financial disclosure/conflicts of interest: H.A., J.N.C.B., S.L., D.L.C., W.G.C., A.A.-K., S.E.M., D.G., M.H.B., G.W., R.P.I., Y.E.S., L.H., S.H., D.V., M.A.P.-V., and J.E.R. have no conflicts to declare. J.L.W., J.H.K., R.R.A., M.A.H., R.K.L., T.G., V.G., D.J.Z., Y.L., P.K., and B.A.R. sole disclosure is that they receive grant support from NIH. L.R.P. received grant support from NIH and has been a speaker for Allergan. He also served as a paid consultant to Novartis and to Bausch + Lomb. He has received support to travel to meetings by The Glaucoma Foundation (NYC), Glaukos and Aerie Pharmaceuticals. J.S.S. received grant support from NIH and is an inventor on a patent. J.F. received grant support from NIH and Regeneron. D.L.B. received consulting fees from Alcon Labs and travel support from New World Medical, Inc. He is also compensated for Data Safety Monitoring Board activity from Ivantis. He received grant support from New World Medical. T.R. received grant support from NIH and is a consultant for Alcon, Alimera, Bausch and Lomb, Reichert, Sensimed, and Inotek. W.K.S. holds a patent regarding the use of genetic data for risk assessment in age-related macula degeneration (Duke University). He received grant support from NIH, Florida Biomedical Research Program and the American Health Assistance Foundation. K.S. is a consultant to Alcon, Allergan, Santen, and Shire. A.H.S. serves as a consultant to Allergan, Alcon and Sensimed. He has received research support from NIH, Aerie Pharmaceuticals, and Glaukos. R.R. is on the advisory board of Isonic Inc, Intelon Optics and Xoma (US) LLC. He serves as consultant for Aeon Astron Europe B.V., Diopsyc, Inc, GLIA LLC, Gerson Lehrman Group, Guardian Health Sciences and Mobius Therapeutics. He is on the Board of Directors for International Eye Wellness Institute and receives royalties from Ocular Instruments. D.J.R. received research support from Merck, Allergan, Ivantis, and Glaukos. He is on the Scientific Advisory Board of Aerie and Transcend and is on the Data Safety Monitoring Board of Sanofi. F.M. received research support from Carl-Zeiss Meditec, Heidelberg Engineering, Allergan, Topcon, Reichert and Genentech. R.N.W. had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon; Allergan; Bausch & Lomb Incorporated; ForSight VISION5; and Valeant; Contracted Research: Genentech, Inc; and Quark. J.L.H. receives travel support and speaker honoraria from Novartis. He has received royalties from John Wiley and Sons and Athena Diagnostics. The NIH supports his research.